Fusion Antibodies (LON:FAB) Stock Price Down 6.7% – Time to Sell?

Fusion Antibodies plc (LON:FAB) fell 6.7% during trading on Tuesday. The stock traded as low as GBX 10.11 and last traded at GBX 10.50. Approximately 452,178 shares changed hands during mid-day trading, an increase of 9% from the average session volume of 415,391 shares. The stock had previously closed at GBX 11.25.

Fusion Antibodies Stock Up 3.6%

The company has a quick ratio of 2.36, a current ratio of 2.82 and a debt-to-equity ratio of 20.41. The company has a market capitalization of £12.96 million, a price-to-earnings ratio of -10.36 and a beta of 1.24. The stock’s fifty day moving average price is GBX 11.02 and its 200-day moving average price is GBX 11.94.

Fusion Antibodies (LON:FAB) last announced its earnings results on Monday, September 14th. The company reported GBX (1.20) EPS for the quarter. Fusion Antibodies had a negative return on equity of 97.87% and a negative net margin of 54.45%. On average, sell-side analysts predict that Fusion Antibodies plc will post -129.9999875 earnings per share for the current fiscal year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.